Decorin-mediated oncosuppression - a potential future adjuvant therapy for human epithelial cancers

British Journal of Pharmacology
Annele O Sainio, Hannu T Järveläinen

Abstract

Currently, the multifaceted role of the extracellular matrix (ECM) in tumourigenesis has been realized. One ECM macromolecule exhibiting potent oncosuppressive actions in tumourigenesis is decorin, the prototype of the small leucine-rich proteoglycan gene family. The actions of decorin include its ability to function as an endogenous pan-receptor tyrosine kinase inhibitor, a regulator of both autophagy and mitophagy, as well as a modulator of the immune system. In this review, we will discuss these topics in more detail. We also provide a summary of preclinical studies exploring the value of decorin-mediated oncosuppression, as a potential future adjuvant therapy for epithelial cancers. LINKED ARTICLES: This article is part of a themed section on Translating the Matrix. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.1/issuetoc.

References

Feb 10, 1997·The Journal of Cell Biology·K G DanielsonR V Iozzo
Mar 17, 1999·Proceedings of the National Academy of Sciences of the United States of America·R V IozzoI Eichstetter
Jan 18, 2003·The International Journal of Biochemistry & Cell Biology·Achilleas D TheocharisDimitrios A Theocharis
Mar 13, 2003·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·J Guilherme TralhãoPatricia Lemarchand
Jul 23, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jörg KöningerHelmut Friess
Feb 4, 2005·Oncogene·Charles C ReedRenato V Iozzo
Jun 1, 2005·The Journal of Biological Chemistry·Konerirajapuram N SulochanaRuowen Ge
Jan 6, 2006·Journal of Clinical Pathology·J KöningerH Friess
Apr 1, 2008·The International Journal of Biochemistry & Cell Biology·Huapeng FanRuowen Ge
Aug 9, 2008·The American Journal of Pathology·Silvia GoldoniRenato V Iozzo
Jan 29, 2013·The FEBS Journal·Andrea MorrioneRenato V Iozzo
Apr 23, 2013·Chinese Journal of Cancer·Xiu-Li Bi, Wancai Yang
Aug 14, 2013·Scientific Reports·Yong LiGary J Fisher
Nov 26, 2013·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Xiang YuXiuhua Zhang
Nov 28, 2013·PloS One·Rebecca A ScottAlyssa Panitch
Jan 30, 2014·Matrix Biology : Journal of the International Society for Matrix Biology·Atul GoyalRenato V Iozzo
Feb 18, 2014·Atherosclerosis·Lisa R Tannock
Feb 11, 2015·Matrix Biology : Journal of the International Society for Matrix Biology·Hannu JärveläinenThomas N Wight
May 24, 2015·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·Marie C NymanHannu T Järveläinen
Jul 16, 2015·Biochemistry·Thomas NeillRenato V Iozzo
Nov 3, 2015·Advanced Drug Delivery Reviews·Thomas NeillRenato V Iozzo
Dec 24, 2015·BioMed Research International·Tero A H Järvinen, Stuart Prince
Feb 5, 2016·Experimental Cell Research·Nelly El ShafeyAntoine Kichler
Mar 10, 2016·Journal of Controlled Release : Official Journal of the Controlled Release Society·A-Rum YoonChae-Ok Yun
Jun 17, 2016·Molecular & Cellular Oncology·Thomas NeillRenato V Iozzo
Oct 19, 2016·Matrix Biology : Journal of the International Society for Matrix Biology·Maria A GubbiottiRenato V Iozzo
Nov 20, 2016·The FEBS Journal·Liliana SchaeferRenato V Iozzo
Dec 3, 2016·Nucleic Acids Research·Minoru KanehisaKanae Morishima
Feb 9, 2017·The Journal of Biological Chemistry·Annabel TorresRenato V Iozzo

❮ Previous
Next ❯

Citations

Apr 23, 2019·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·Marie C NymanHannu T Järveläinen
Jul 7, 2020·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·Jinyang Zeng-BrouwersLiliana Schaefer
Dec 14, 2018·British Journal of Pharmacology·James R WhitefordGiulia De Rossi
Feb 23, 2020·Frontiers in Pharmacology·Tanaya Walimbe, Alyssa Panitch
Aug 10, 2021·World Journal of Clinical Oncology·Yun Zhu, Annie Lai Man Cheung
Dec 11, 2021·Frontiers in Oncology·Lu DengRu Zhang

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02865031
NCT00062907

Related Concepts

Related Feeds

Parkinson's Disease & Autophagy (MDS)

Autophagy leads to degradation of damaged proteins and organelles by the lysosome. Impaired autophagy has been implicated in several diseases. Here is the role of autophagy in Parkinson’s disease.

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

Autophagy & Model Organisms

Autophagy is a cellular process that allows degradation by the lysosome of cytoplasmic components such as proteins or organelles. Here is the latest research on autophagy & model organisms

Autophagy & Metabolism

Autophagy preserves the health of cells and tissues by replacing outdated and damaged cellular components with fresh ones. In starvation, it provides an internal source of nutrients for energy generation and, thus, survival. A powerful promoter of metabolic homeostasis at both the cellular and whole-animal level, autophagy prevents degenerative diseases. It does have a downside, however--cancer cells exploit it to survive in nutrient-poor tumors.

Autophagy & Disease

Autophagy is an important cellular process for normal physiology and both elevated and decreased levels of autophagy are associated with disease. Here is the latest research.

Related Papers

British Journal of Pharmacology
James R WhitefordGiulia De Rossi
Matrix Biology : Journal of the International Society for Matrix Biology
Simone BuraschiRenato V Iozzo
European Journal of Cell Biology
David Denis Sofeu FeugaingManuela Viola
© 2022 Meta ULC. All rights reserved